A patient-focused, clinical-stage immuno-oncology startup. Our lead candidate, #OS2966, is FDA Orphan Drug Designated for glioblastoma and ovarian cancer.
Stamford, CT
Joined April 2011
- Tweets210
- Following45
- Followers278
- Likes56
Congrats @EKNduom 🎉! We are excited to continue collaborating on impactful research with you.
I am honored to announce that I was awarded the Daniel Louis Barrow Endowed Chair in Neurosurgery @emoryneurosurgery. I would like to thank my family, my mentors and mentees, colleagues, friends, and the philanthropic support that made this possible:
news.emory.edu/stories/2023/…
Congrats Chibueze! The entire OncoSynergy team is proud of you!
You’re unable to view this Post because this account owner limits who can view their Posts. Learn more
“There is no limit to what we, as women, can accomplish.” - Michelle Obama
Happy International Women's Day from this woman-led company dedicated to treating rare and resistant cancers.
#internationalwomensday
1
135
Trailblazers 💫 #WomensHistoryMonth
Pictured:
- (top left) Dr. Jane C. Wright is known for promoting chemotherapy as a viable treatment option for patients.
1
117
- (bottom left) Dr. Rosalind Franklin was a chemist and X-ray crystallographer whose Photo 51 revealed the double helix of DNA — an essential discovery in understanding DNA.
1
69
February is Black History Month and OncoSynergy would like to celebrate a pioneer in the oncology space - Dr. Jane Cooke Wright.
#BHM #BlackHistory #BlackHistoryMonth
1
1
121
🧬 Was the Head of the Cancer Chemotherapy Department and Associate Dean at New York Medical College
🧬 Was the first woman to be elected President of the New York Cancer Society
🧬 Was appointed Head of the Cancer Research Foundation at the age of 33.
1
1
77
Over 40% of cancers occur due to preventable causes ( i.e. poor diet, lack of exercise, smoking, sun overexposure). 🍔🌭🛋️🚬🚭☀️
During #NationalCancerPreventionMonth we urge you to make one lifestyle change that can reduce your cancer risk🎗️
2
89
OncoSynergy, Inc. retweeted
Shout out to the team at @OncoSynergy for this accomplishment and our amazing collaborators at @ChildrensLA, led by Yong Mi Kim, MD, PhD.
chla.org/blog/researchla/stu…
"Based on that data from CHLA, the FDA granted OncoSynergy Inc. orphan drug designation for the compound, OS2966, a first-in-class monoclonal antibody that targets a protein called integrin beta-1."
Read more about this exciting work to treat #AML here: chla.org/blog/researchla/stu…